233 related articles for article (PubMed ID: 31749795)
1. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
Front Immunol; 2019; 10():2472. PubMed ID: 31749795
[TBL] [Abstract][Full Text] [Related]
2. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
Xu A; Zhang L; Chen Y; Lin Z; Li R
Cancer Immunol Immunother; 2017 Feb; 66(2):181-192. PubMed ID: 27872951
[TBL] [Abstract][Full Text] [Related]
4. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical development of neoantigen vaccines.
Li L; Goedegebuure SP; Gillanders WE
Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
[TBL] [Abstract][Full Text] [Related]
8. Expanding the Potential of Neoantigen Vaccines: Harnessing Bacille Calmette-Guérin Cell-Wall-Based Nanoscale Adjuvants for Enhanced Cancer Immunotherapy.
Liu K; Peng J; Guo Y; Li Y; Qi X; Duan D; Li T; Li J; Niu Y; Han G; Zhao Y
ACS Nano; 2024 May; 18(18):11910-11920. PubMed ID: 38680054
[TBL] [Abstract][Full Text] [Related]
9. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
10. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
11. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
12. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
Lynn GM; Sedlik C; Baharom F; Zhu Y; Ramirez-Valdez RA; Coble VL; Tobin K; Nichols SR; Itzkowitz Y; Zaidi N; Gammon JM; Blobel NJ; Denizeau J; de la Rochere P; Francica BJ; Decker B; Maciejewski M; Cheung J; Yamane H; Smelkinson MG; Francica JR; Laga R; Bernstock JD; Seymour LW; Drake CG; Jewell CM; Lantz O; Piaggio E; Ishizuka AS; Seder RA
Nat Biotechnol; 2020 Mar; 38(3):320-332. PubMed ID: 31932728
[TBL] [Abstract][Full Text] [Related]
13. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
[TBL] [Abstract][Full Text] [Related]
14. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.
Huff AL; Longway G; Mitchell JT; Andaloori L; Davis-Marcisak E; Chen F; Lyman MR; Wang R; Mathew J; Barrett B; Rahman S; Leatherman J; Yarchoan M; Azad NS; Yegnasubramanian S; Kagohara LT; Fertig EJ; Jaffee EM; Armstrong TD; Zaidi N
JCI Insight; 2023 Dec; 8(23):. PubMed ID: 38063199
[TBL] [Abstract][Full Text] [Related]
15. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
16. Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.
Fritsch EF; Ott PA
Cancer Res; 2024 Apr; 84(7):953-955. PubMed ID: 38558128
[TBL] [Abstract][Full Text] [Related]
17. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
18. Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy.
Zhang Y; Zuo B; Yu Z; Zhao K; Zhang Y; He K; Seow Y; Yin H
Mol Ther; 2023 Dec; 31(12):3579-3593. PubMed ID: 37919900
[TBL] [Abstract][Full Text] [Related]
19. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
Lu L; Ma W; Johnson CH; Khan SA; Irwin ML; Pusztai L
Vaccine; 2023 Mar; 41(12):2073-2083. PubMed ID: 36813666
[TBL] [Abstract][Full Text] [Related]
20. Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope.
Li B; Jing P; Zheng G; Pi C; Zhang L; Yin Z; Xu L; Qiu J; Gu H; Qiu T; Fang J
Signal Transduct Target Ther; 2023 Oct; 8(1):397. PubMed ID: 37848417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
